Woodline Partners LP Buys 86,540 Shares of Insmed, Inc. $INSM

Key Points

• Woodline Partners LP increased its stake in Insmed, Inc. by 53.3%, acquiring an additional 86,540 shares and now holding approximately 0.14% of the company valued at $18.98 million.
• Multiple analysts have raised their price targets for Insmed, with Bank of America setting a target of $109 and Truist Financial increasing theirs to $139, while the average target price among analysts is $139.86.
• Insmed's CEO sold over 129,805 shares at a price of $100.39, which represents a significant decrease in their ownership, highlighting insider transactions amid market activity.

Woodline Partners LP grew its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 53.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 248,770 shares of the biopharmaceutical company's stock after purchasing an additional 86,540 shares during the period. Woodline Partners LP owned approximately 0.14% of Insmed worth $18,979,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. M&T Bank Corp boosted its stake in shares of Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. Snowden Capital Advisors LLC boosted its stake in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after acquiring an additional 158 shares in the last quarter. Cullen Frost Bankers Inc. boosted its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Insmed by 6.5% during the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after acquiring an additional 228 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in Insmed by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock worth $2,463,000 after acquiring an additional 235 shares in the last quarter.

Analysts Set New Price Targets

INSM has been the topic of several research reports. William Blair initiated coverage on shares of Insmed in a research note on Wednesday, August 20th. They set an "outperform" rating on the stock. Bank of America lifted their price objective on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Truist Financial lifted their price objective on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Morgan Stanley lifted their price objective on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Finally, UBS Group lifted their price objective on Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $139.86.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 129,805 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at $23,483,630.36. This represents a 35.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Roger Adsett sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares in the company, valued at approximately $13,477,168.46. This trade represents a 19.14% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 378,382 shares of company stock valued at $40,169,038. 3.00% of the stock is currently owned by insiders.

Insmed Trading Down 0.9%

Shares of NASDAQ INSM opened at $145.93 on Thursday. The firm's 50 day moving average price is $117.50 and its 200-day moving average price is $90.98. The company has a market cap of $30.85 billion, a PE ratio of -25.56 and a beta of 0.97. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $149.08. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.